Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-Current Assets: 2023-2024

Historic Non-Current Assets for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $6.5 million.

  • Contineum Therapeutics' Non-Current Assets rose 564.42% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 564.42%. This contributed to the annual value of $6.5 million for FY2024, which is 141.01% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Non-Current Assets of $6.5 million as of FY2024, which was up 141.01% from $2.7 million recorded in FY2023.
  • Contineum Therapeutics' 5-year Non-Current Assets high stood at $6.5 million for FY2024, and its period low was $2.7 million during FY2023.
  • For the 2-year period, Contineum Therapeutics' Non-Current Assets averaged around $4.6 million, with its median value being $4.6 million (2023).
  • Data for Contineum Therapeutics' Non-Current Assets shows a peak YoY surged of 141.01% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Non-Current Assets (Yearly) stood at $2.7 million in 2023, then spiked by 141.01% to $6.5 million in 2024.